Back to top

Image: Bigstock

CytoDyn (CYDY) Enrolls First Patient in NASH Study on Leronlimab

Read MoreHide Full Article

CytoDyn (CYDY - Free Report) Enrolls First Patient in NASH Study on Leronlimab

CytoDyn Inc. ((CYDY - Free Report) ) announced that it has enrolled the first patient in the phase II study evaluating its CCR5 antagonist candidate, leronlimab, for the treatment of nonalcoholic steatohepatitis (NASH).

NASH is a chronic liver disease characterized by the presence of hepatic inflammation and cell injury. The company’s preclinical study demonstrated strong positive data, highlighting the potential of leronlimab in treating nonalcoholic fatty liver disease (NAFLD), a common precursor to NASH.

CytoDyn’s shares have surged 147.5% so far this year against the industry’s decline of 2%.

This is a 60-patient, placebo-controlled phase II two-arm study being conducted to assess the efficacy of leronlimab in adult patients with NASH. The study uses advanced MRI technology to monitor fatty deposition via proton density fat fraction and fibrosis by CT1 analysis without invasive biopsy.

Notably, leronlimab is being developed for multiple cancer indications.

We also note thatCytoDyn completed its phase II study (CD10) of leronlimabfor COVID-19 in the United States, which produced statistically significant results. Enrollment continues in its phase IIb/III study for the severe-to-critically ill COVID-19 population in several hospitals and clinics across the United States.

Zacks Rank & Stocks to Consider

CytoDyn currently carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the healthcare sector include ASLAN Pharmaceuticals Ltd. (ASLN - Free Report) , Aptose Biosciences Inc. (APTO - Free Report) and Alimera Sciences Inc. (ALIM - Free Report) . All of them carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

ASLAN’s loss per share estimates have narrowed from 42 cents to 40 cents for 2020 and from 60 cents to 57 cents for 2021 over the past 60 days.

Aptose’s loss per share estimates have narrowed from 77 cents to 69 cents for 2020 and from 85 cents to 81 cents for 2021 over the past 60 days.

Alimera’s loss per share estimates have narrowed from $1.31 to 96 cents for 2020 over the past 60 days.


These Stocks Are Poised to Soar Past the Pandemic

The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking. Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.

See the 5 high-tech stocks now>>

Published in